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Abstract
Background: Although sub-Saharan Africa (SSA) is particularly affected by sickle cell disease (SCD), there is dearth
of research on this topic in the region, specifically targeting the magnitude of SCD-related complications. We
therefore conducted this study to determine the burden of acute chest syndrome (ACS) and describe its clinical
and therapeutic aspects among SCD children in Cameroon, a SSA country.
Methods: This was a retrospective study carried-out from September 2013 to June 2014 at the SCD unit of the
Mother and Child Centre of the Chantal Biya Foundation, a pediatric reference centre in Yaoundé, Cameroon. We
enrolled all SCD children with confirmed diagnosis of ACS, and recorded their clinical presentation at admission
along with their evolution during hospitalization.
Results: Twenty one cases of ACS were identified during the study period, from 338 hospitalizations of children
with SCD. Ages ranged from 11 months to 16 years with a mean (standard deviation) of 5.5 (3.4) years, and a male/
female sex ratio of 3.2/1. We noticed relatively low levels of HbF, from 6.4 to 21.9 % with a mean of 14.6 % (6.0 %).
The three main symptoms at admission were fever (90.5 %), cough (81 %) and chest pains (28.6 %). Two patients
(9.5 %) developed ACS 2 days after admission. The mean values of leukocytes, neutrophils, serum CRP, serum LDH
and hemoglobin were respectively 32479.4 (17862.3)/mm3, 23476 (11543.7)/mm3, 228.2 (132.6) mg/l, 3452.3 (2916.3)
IU/l and 6.5 (1.2) g/dl. The main localizations of radiological alveolar consolidations were the lower lobes (90.5 %).
Treatment associated broad-spectrum antibiotics (100 %), hydration (100 %), analgesics (43.2 %), whole blood
transfusion (66.7 %), and oxygen supplementation (33.3 %). Blood transfusion significantly improved hemoglobin
level (p = 0.039). The duration of hospitalization, the mean of which was 6.8 (3.1) days, was influenced by none of
the tested variables (all p values > 0.05).
Conclusion: ACS is frequent among SCD children in our milieu. Its etiologies seem to be multifactorial. Patients’
parents should be educated to recognize early signs and symptoms of the disease, and consult rapidly.
Additionally, clinicians must be trained to diagnose ACS, and manage it promptly and efficiently to avoid its related
catastrophic consequences.
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Background
Sickle cell disease (SCD), described for the first time by
Herrick in 1910, is an autosomal recessively inherited gen-
etic disorder caused by a single point mutation in the gene
encoding the β-globin chain of hemoglobin [1, 2]. It is the
most widespread and severe monogenetic disorder in the
world [3], especially in sub-Saharan Africa (SSA) where it
represents a real public health hazard with 1 to 4 % of
babies born affected [4]. SCD is associated with multiple
acute and chronic complications such as painful vaso-
occlusive events, cerebral vasculopathy, priapism, chronic
kidney disease, acute chest syndrome (ACS) and pulmon-
ary hypertension among others [5, 6].
ACS is an acute lung injury syndrome that occurs fre-
quently in patients with SCD. Indeed, it is the second most
common cause of hospitalization, and the leading cause of
death, contributing to almost 25 % of SCD-related mortality
[7, 8]. Moreover, nearly half of deaths due to ACS occur in
SCD patients less than 20 years of age [9]. Repeated
episodes of ACS negatively impact long-term lung function,
resulting thereby in chronic lung diseases [10].
ACS is currently defined as a new pulmonary infiltrate
on chest X-ray consistent with alveolar consolidation but
not atelectasis, in conjunction with at least one of the
following clinical findings: fever (>38.5 °C), reduced oxy-
gen saturation or PaO2 (<60 mmHg), tachypnea, inter-
costal retractions, nasal flaring or accessory muscle use,
chest pain, cough, wheeze or rales [11, 12]. In 1979,
Charache et al. [13] first suggested using the term “acute
chest syndrome” for this complication, acknowledging
the difficulties in determining its pathogenesis. Till now-
adays, the pathophysiology of ACS remains not fully
elucidated, yet multiple risk factors have been identified
including: male sex, younger age, higher steady-state of
leukocyte counts and hemoglobin level, lower hemoglobin
F (HbF) concentrations, previous history of ACS, history
of asthma, active smoking or environmental smoke expos-
ure. Furthermore, ACS may be more severe in individuals
with HbSS as compared with HbSC disease [6, 7, 14–17].
The etiology of ACS is multifactorial. The three primary
studied mechanisms include pneumonia or systemic infec-
tion, fat embolism, and direct pulmonary infarction from
HbS-containing erythrocytes [6, 11, 18]. The management
of this condition is still largely determined by the experi-
ence of individual practitioners, and currently there are no
conclusive randomized controlled clinical trials to guide
therapy [19]. The most common therapy includes nonspe-
cific supportive care strategies aimed at hastening recov-
ery to baseline, including: hospitalization, hydration,
analgesics, broad-spectrum antibiotics, bronchodilators,
incentive spirometry, supplemental oxygen, and blood
transfusions [6, 11, 18, 19].
Although SSA is particularly affected by SCD [4], there
is paucity of data on this topic in the region, specifically
targeting the magnitude of SCD-related complications.
This study was thus undertaken, aiming at determining
the burden of ACS and describing its clinical and thera-
peutic aspects among SCD children in a SSA tertiary
pediatric health care facility.
Methods
Study setting and participants
This was a retrospective study conducted from Septem-
ber 2013 to June 2014 at the SCD unit of the Mother
and Child Centre of the Chantal Biya Foundation. This
is a pediatric reference Centre located in Yaoundé, the
capital city of Cameroon, a SSA country. This tertiary
health care facility receives almost 31,000 consultations
with almost 7,000 hospitalizations annually, with pa-
tients coming from all over the country. Its SCD unit
was opened in December 2008, and is used to dealing
with routine out-patient consultations as well as daily
follow-up of hospitalized SCD children.
We consecutively and exhaustively included all the pa-
tients aged below 18 years and hospitalized in the SCD
unit during the study period. These were known SCD chil-
dren and adolescents with a confirmed diagnosis of ACS
(at entry or during hospitalization). The diagnosis of ACS
was based on a new radiological alveolar consolidation at
the chest X ray, alongside clinical signs and/or symptoms,
in keeping with Ballas et al. [12], namely: fever (>38.5 °C),
reduced oxygen saturation, tachypnea, intercostal retrac-
tions, nasal flaring or accessory muscle use, chest pain,
cough, wheeze or rales. Patients who did not perform a
chest X ray or whose chest X ray did not show any radio-
logical alveolar consolidation were not included in the
study. Data were recorded on socio-demographic charac-
teristics, past medical history and events, main complaints
and clinical examination at entry, biological and radio-
logical exams (full blood count, thick blood smear, hemo-
cultures, serum CRP (normal < 6 mg/l), serum LDH
(normal range 313–618 IU/l)) as well as the administered
treatment and evolution during hospitalization.
Statistical methods
Statistical analyses used SPSS, version 20.0 (SPSS Inc,
Chicago, Illinois, USA). Results are expressed as mean
(Standard Deviation) or count (proportion) as appropriate.
Qualitative variable comparisons used the χ2 test or equiv-
alents, and that of quantitative ones, the Student t test for
paired samples or non-parametric equivalents. Odds ratios
(OR) with 95 % confidence intervals (CI) were used to ap-
preciate the impact of different variables on the duration
of hospital stay, and were calculated by logistic regression
analyses. A p value < 0.05 was used to characterize statisti-
cally significant results.
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Ethical considerations
All the procedures used in this survey were in accordance
with the current revision of the Helsinki Declaration. This
study received approval from the authorities of the
Mother and Child Centre of the Chantal Biya Foundation,
and was delivered an ethical clearance by the Ethical
Review Board of the Faculty of Medicine and Biomedical
Sciences, University of Yaoundé I, Cameroon. As the study
was retrospective, we could not obtain participants’ par-
ents/guardians’ consent. Nonetheless, the need for consent
was waived by the just-cited institutional review board.
Results
We recorded on the whole 21 cases of ACS during the
study period, on 338 hospitalizations of children with
SCD, hence an in-patient prevalence of 6.2 %. Table 1 dis-
plays the study population’s general profile. Ages ranged
from 11 months to 16 years, with a mean of 5.5 (3.4)
years, and males were more represented than females with
a sex ratio of 3.2/1 (Tables 1 and 2). Only seven patients
had a hemoglobin electrophoresis dating back to less than
one year, HbS ranging from 55 % to 86 % with a mean of
75.1 (11.9) %, and HbF, from 6.4 % to 21.9 % with a mean
of 14.6 (6.0) % (Table 2). Only 38.1 % of children were
regularly followed-up, i.e. were used to visiting the unit for
a check-up at least every 3 months. Besides, not more
than 33.3 % of our patients had been adequately vacci-
nated in accordance with their ages, and only 3 children
aged 0–5 years (27.3 %) were currently taking an antibiotic
prophylaxis (Table 1).
According to our patients’ parents, duration of evolution
of symptoms before consultation ranged from less than
24 h to almost 14 days, with a mean of 4.8 (4.2) days. The
presenting complaints are reported in Table 3. The three
main symptoms were fever (90.5 %), cough (81 %), and
chest pains (28.6 %). The main clinical signs we observed
were pulmonary consolidation (100 %), an altered general
appearance (61.9 %), clinical signs of anemia (57.1 %), a
systemic inflammatory response syndrome (57.1 %), and
signs of respiratory distress (33.3 %). Two patients (9.5 %)
who were initially admitted for vaso-occlusive crises
(VOC) developed ACS after 2 days of hospitalization.
Results of biological tests showed very high levels of
leukocytes, neutrophils, serum CRP and serum LDH. In-
deed, their mean values were 32479.4 (17862.3)/mm3,
23476 (11543.7)/mm3, 228.2 (132.6) mg/l, and 3452.3
(2916.3) IU/l respectively. Contrariwise, we observed
relatively low levels of hemoglobin, with a mean of 6.5
(1.2) g/dl (Table 2). The main localizations of radiological
alveolar consolidations were the lower lobes (90.5 %). None
of the 10 hemocultures performed was positive, and only
one of the 15 thick blood smears performed to seek for
malaria parasites was positive to Plasmodium species, spe-
cifically Plasmodium falciparum (6.7 %; Table 3).
Patients were placed on two to three antibiotics: a beta-
lactam (either ampicillin or ceftriaxone) + a macrolide
(oral azithromycin) ± an aminoglycoside (gentamicin)
(Table 4). Two days after the fever had dropped, patients
were switched to oral cephalosporin (cefixim) or amoxicil-
lin accordingly, for a total duration of 10 to 14 days (both
intravenously and orally). Two patients (9.5 %) initially
placed on ceftriaxone were still presenting fever on the
fourth day of antibiotherapy; they were subsequently
switched to vancomycin for seven days with a good im-
provement. Adjuvant therapy included hyperhydration
(100 %), paracetamol (100 %) for fever or pains, tramadol
(42.9 %) and ibuprofen (23.8 %). Fourteen patients
(66.7 %) were transfused with whole blood, and all of them
concurrently received an anti-malarial treatment to pre-
vent transfusion-transmitted malaria. All the seven pa-
tients (33.3 %) who presented signs of respiratory distress
were placed on oxygen, its duration ranging from 1 to
5 days with a mean of 3.6 (1.6) days (Tables 2, 3 and 4).
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Adequately vaccinated for the age
No 14 66.7
Yes 7 33.3
Currently taking folic acid
No 12 52.1
Yes 9 47.9
Currently taking antibiotic prophylaxis
For the 0–5 years old (N = 11)
No 8 72.7
Yes 3 27.3
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A control full blood count was performed only by seven
of our patients 48 h after blood transfusion (Table 3). We
did not find any statistical difference between the first and
second leukocyte counts (p = 0.711), this being the same
for neutrophil counts (p = 0.811). By contrast, we did no-
tice a significant increase in hemoglobinemia (p = 0.039).
The duration of hospitalization ranged from 3 to 12 days
with a mean of 6.8 (3.1) days. One patient of the female
sex died on the fourth day of hospitalization, hence a mor-
tality rate of 4.8 % (Tables 2 and 4). While investigating
factors that could have impacted the duration of
hospitalization, we found that age, sex, regular follow-up,
immunization status, duration of evolution of symptoms
prior to consultation, transfusion, oxygen, and the anti-
biotic used were not implicated in the determination of
duration of hospitalization (all p values > 0.05 as depicted
by Table 5).
Discussion
This study showed that ACS accounted for 6.2 % of SCD
children hospital admissions with almost 2.1 SCD
patients presenting ACS per month. This proportion is
comparable to the 1.9 ACS episodes/month among hos-
pitalized SCD children in Bruxelles [15], and higher than
the 1.4, 0.3 and 0.2 ACS episodes/month respectively
reported in Brazzaville, Antananarivo and French Guiana
[20–22]. However, our prevalence of ACS is lower than
the 10–20 % rate of hospital admissions reported by
Miller and Gladwin in their review [6]. Our prevalence
may be an underestimate of the real burden of ACS
among our children suffering from SCD for some rea-
sons. First, hemoglobin electrophoresis is not systematic-
ally performed in our milieu, and many parents neither
know their status nor that of their kids. As we consid-
ered only known SCD patients, some unknown SCD
patients may have presented this condition and escaped
from enrolment. Second, due to parents’ financial con-
straints, we are used to performing just one chest x-ray
during hospitalization. As a result, we could have missed
all those whose first chest x-ray was normal but who
developed ACS later on, given that radiographic findings
in case of ACS may progress over time [9, 11, 23]. If it is
true that a positive chest x-ray is the key element to
define the disease [12], there have been some claims that
a single negative chest x-ray cannot exclude the disease
[23–25], taking into account that clinical assessment
may appear inadequate to identify ACS [11]. It has been
also suggested that every SCD patient presenting with
fever must undergo a chest x-ray [11, 24].
Consequently, close clinical monitoring alongside ser-
ial radiographic evaluation (without ignoring the risk of
radiation) is necessary. In fact, it has been shown that
ACS may develop 1 to 3 days after admission for VOC
as there may exist a close relationship between ACS and
VOC [6, 11, 15, 24]. This is truer for adults than chil-
dren, as the latter usually present with ACS at admission
[26]. In our study for instance, only 2 children (9.5 %)
developed ACS 2 days after admission, and pains were
concomitantly associated in 52.4 % of cases. Some risk
factors involved in the development of ACS during hos-
pital stay have been identified such as the male sex, past
medical history of ACS, thoracic pains at entry and use
of morphine during hospitalization [15, 27].
Although we did not assess risk factors of developing
ACS, we observed a male predominance and relatively
low levels of HbF, in line with the literature [6, 16, 17]. We
also found that fever (90.5 %), cough (81 %) and thoracic
pains (28.6 %) were the main symptoms in keeping with
previous reports [9, 21, 28], these symptoms being mainly
in favor of pulmonary infections. Despite the fact that we
Table 2 Summary of quantitative variables
Variable Min Max Mean SD Median IQR
Age (years) N = 21 0.92 16 5.5 3.4 5.0 3.4–7
HbS (%) N = 7 55 86 75.1 11.9 77.9 66–86
HbF (%) N = 7 6.4 21.9 14.6 6.0 14.8 9.7–19.7
Leukocytes (/mm3) N = 18 10600 73900 32479.4 17862.3 30295 19050–37875
Neutrophils (/mm3) N = 18 4800 51600 23476 11543.7 24100 11600–28100
Hemoglobinemia (g/dl) N = 18 4.9 8.4 6.48 1.15 6.25 5.4–7.6
Serum LDH (UI/l) N = 11 1307 10366 3452.3 2916.3 2093 1623–5301
Serum CRP (mg/l) N = 14 4.5 432 228.2 132.6 233.5 89–326
Leukocytesa (/mm3) N = 7 8300 39100 21557.2 11843.3 18900 11000–35200
Neutrophilsa (/mm3) N = 7 5800 29716 16319.3 10892.7 13400 6475–29100
Hemoglobinemiaa (g/dl) N = 7 7.5 13.9 9.6 2.3 9.4 7.5–10.6
Duration of oxygen therapy (days) N = 7 1 5 3.6 1.6 4 2–5
Duration of hospitalization (days) N = 21 3 12 6.8 3.1 6 5–9.5
acontrol values
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did not have our patients’ baseline leukocyte counts (ex-
plained by the fact that many of our patients are not
regularly followed-up and are from financially-limited
families), we noticed very high leukocyte counts [32479
(17862) mm3], especially neutrophils [23476 (11543)
mm3], associated with elevated serum CRP levels [228.2
(132.6]. These elements are also strongly suggestive that
infection may initiate or precipitate the development of
ACS among our patients, corroborating previous reports
elsewhere [15, 16]. However, though blood culture was
not performed in all patients, no germ was identified. This
result was also reported by Rucknagel et al. [25] who in-
criminated rib infarction as the main etiology of ACS. But
without invasive procedures (bronchoscopy with broncho-
alveolar lavage), it is very difficult to rule out conclusively
a bacterial infection as a cause of ACS. Microorgan-
isms that have been identified associated with ACS
include Streptococcus pneumonia, Chlamydiae pneumo-
nia, Mycoplasma pneumonia, influenza virus A H1N1,
parainfluenza virus, respiratory syncytial virus and corona-
virus among others [15, 21, 23].
Besides, we observed that radiological abnormalities of
the lower lobes (90.5 %) were the prevailing ones, mirror-
ing previous findings [23, 28]. Contrariwise, other studies





Duration of evolution of symptoms before
consultation
≤ 48 h 6 28.6




Thoracic pains 6 28.6
Generalized pains 6 28.6
Abdominal pains 5 23.8
Dyspnea 5 23.8
Asthenia 2 9.5




Altered general appearance 13 61.9
Pulmonary consolidation 21 100
Clinical anemia 12 57.1
Respiratory distress 7 33.3
Systemic inflammatory response syndrome 12 57.1
Jaundice 2 9.5
Hemoglobinuria 1 4.8
Result of the chest X ray
Right upper lobe consolidation 2 9.5
Right middle and lower lobes
consolidation
2 9.5
Right lower lobe consolidation 12 57.1
Left lower lobe consolidation 3 14.3
Right and left lower lobes consolidation 2 9.5
Hemocultures
Not done 11 52.4
Negative 10 47.6
Positive 0 0
Malaria parasitemia (by thick blood smear)
Not done 6 28.6
Negative 14 66.7
Positive 1 4.8
Table 4 Management and outcome
Number (N = 21) Percentage (%)
Antibiotherapy
Beta-lactam
Ceftriaxone (IV: 50 mg/kg/day) 10 47.6
Ampicillin (IV: 50 mg/kg/8 h) 11 52.4
Gentamicin (IV: 3 mg/kg/day) 16 76.2
Azithromycin (oral: 5-10 mg/kg/day) 21 100
Adjuvant therapy
Tramadol (IV: 1–2 mg/kg/6 h) 9 42.9
Paracetamol (oral or IV:
15 mg/kg/6 h)
21 100
Ibuprofen (oral: 10 mg/kg/8 h) 5 23.8














≤ 5 days 8 38.1
> 5 days 13 61.9
aBS = Body surface; IV = intravenous
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showed that the main radiological localizations of ACS
were the upper lobes in children, and the lower ones in
adults [9, 20]. While the upper lobes predominance
has been associated with an infectious etiology espe-
cially in children, the lower or multi-lobes predomin-
ance has been linked to pulmonary thrombosis and
fat embolism [9, 16, 20] or rib infarction [25]. Our results
are therefore suggestive that the pathogenesis of ACS in
our setting is also multifactorial. Further well-designed
studies with large sample sizes are warranted to better elu-
cidate the etiology of ACS in our setting.
In line with the literature [6, 19, 22], our management
of ACS included broad-spectrum antibiotherapy, hydra-
tion, analgesics, supplemental oxygen and transfusion, but
none of these supportive care impacted the duration of
hospital stay. Actually, only patients presenting respiratory
distress were placed on oxygen, mainly due to limitation
of resources. Likewise, we transfused only SCD patients
who had a hemoglobin level ≤ 7 g/dl given that blood
safety remains an issue of major concern in the mi-
lieu [29]. Although transfusion did not reduce the
hospital stay, it significantly increased the hemoglobin
level (p = 0.039), perhaps improving therefore the clinical
state of our patients. Early transfusion of SCD patients
presenting with ACS should be encouraged in SSA set-
tings, especially transfusion of packed red blood cells in-
stead of whole blood to reduce transfusion-related adverse
reactions, despite recurrent blood shortages that occur in
the region [30]. Nonetheless, more studies are needed to
underpin this suggestion with robust scientific evidence
and indicate which threshold should be considered to
transfuse SCD children suffering from ACS.
The mean duration of hospitalization we found (6.8 days)
is comparable to the 7 days-duration reported by Bertholdt
et al. [15], but a bit higher than findings from Vichinsky
et al. (5.4 days) [9] and lower than what has been reported
by Vichinsky et al. in another study [23] and Hunald
et al. [21]: more than 10 days and 12 days respectively.
Introduction of other supportive care in our practice
like bronchodilators and incentive spirometry as else-
where [6, 19], along with systematic oxygen supplemen-
tation and early blood transfusion could substantially
reduce the duration of hospital stay. Furthermore, the use
of dexamethasone deserves some close considerations. In
fact, there is body of evidence bolstering that low dose
dexamethasone (0.3 mg/kg/12 × 4 doses) significantly di-
minished the duration of hospital stay, the need for blood
transfusion, oxygen and analgesics use, and duration of
fever, without a rebound effect [31] which was observed
with high dose methylprednisolone in cases of VOC [32].
One of our patients died, hence a mortality rate of 4.8 %
which concurs the 4 % percentage obtained by Bertholdt
et al. in Belgium [15]. This was an inadequately-
vaccinated and unregularly-followed female SCD patient
aged 18 months, with a HbF level of 18.9 %. She was
brought to consult for fever, cough and respiratory dis-
tress, and the chest x-ray revealed medium and lower
right lobes alveolar consolidations. Titers of LDH and
CRP were respectively 10366 IU/l and 414 mg/l. She was
placed on a triple antibiotherapy (ceftriaxone, gentamycin
and azithromycin), oxygen supplementation, and was
transfused as well. But she died at day 4 of hospitalization
in a context of severe sepsis.
Unfortunately, the retrospective design and small sam-
ple size constitute some weaknesses of the present study.
Besides, generalization of our results may be impeded by
the use of data collected from only one hospital centre.
Another limitation is that biological data were incomplete
due to parents’ financial limitations, as the study was not
sponsored. Nonetheless, in this particularly difficult con-
text, we carried-out serious and reliable data collection
and analyses, and have shown that despite the difficulties
in managing our patients, the outcome is relatively similar
when compared with resource-rich settings in terms of
duration of hospital stay and mortality rate. Eventually,
Table 5 Factors influencing the duration of hospitalization
(equal or below 5 days)
Variable Odds ratio 95 % Confidence interval p value
Age
0 – 5 years 0.375 0.061 – 2.305 0.268
> 5 years 1
Sex
Male 1
Female 3.3 0.413 – 26.366 0.262
Regularly followed-up
No 1.042 0.169 – 6.402 0.664
Yes 1
Immunization status
Not good for age 0.300 0.045 – 1.993 0.213
Good for age 1
Duration of symptoms
≤ 48 h 5.5 0.710 – 42.600 0.115
> 48 h 1
Transfusion
No 2.0 0.291 – 13.738 0.410
Yes 1
Oxygen therapy




Ampicillin 1.944 0.322 – 11.756 0.392
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and to the best of our knowledge, this is the first study
conducted in our milieu targeting ACS burden and
presentations.
Conclusion
ACS is frequent among SCD children in our milieu. Its
etiologies seem to be multifactorial including infection,
pulmonary thrombosis and fat embolism. After an initial
normal chest x-ray, especially in a patient presenting with
VOC, repeated clinical evaluation must be conducted and
possible changes in the clinical status should indicate the
necessity of a new radiographic examination. Patients’ par-
ents should be educated to recognize early signs and
symptoms of the disease, and consult rapidly. Additionally,
clinicians must be trained to correctly diagnose ACS, and
manage it promptly and efficiently to avoid its related
catastrophic consequences. Additive treatment such as
incentive spirometry, bronchodilators and even low dose
dexamethasone could perhaps be introduced in our
settings to reduce the hospital stay and hasten recovery.
On recovery, treatment with hydroxyurea should be dis-
cussed to reduce the likelihood of recurrent episodes.
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